Diligence memo · auto-generated · as of July 2, 2026

Pneuma Respiratory, Inc.

Pneuma Respiratory, Inc. looks fair against its niche peers and is active on financing cadence.

Diligence furtherNo decisive signal either way from the public record alone — the call needs primary diligence beyond the filings.

Businessfiled

Pneuma Respiratory, Inc. operates in Pharmaceuticals, based in BOONE.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Pneuma Respiratory, Inc. has raised $3.6M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).

Largest single filing: $3.6M on 2026-07-01.

Most recent recorded round closed around 2026-07-01.

Valuation (modeled)modeled

Provath models Pneuma Respiratory, Inc. at approximately $6.0M (range $2.7M–$9.3M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.98× the median modeled value of Seed Pharmaceuticals companies in 2025–2027 (19 peers) — value vs value, same stage and era. Within the normal band (98% of peer median) for its niche.

Financing rhythm & timingmixed

Last raise under a month ago; this sector typically re-raises about every 13 months.

Raising on or ahead of the sector's normal rhythm.

Comparablesmixed

Capital scale ranks ahead of 37% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 11% of those peers.

Closest niche peers: Kairos Pharma, LTD., Branch Therapeutics, Inc., ResBiotic Nutrition, Inc., Califia Pharma, Inc., BTB Therapeutics, Inc..

Peoplefiled

6 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.